TY - JOUR
T1 - Vitamin D therapy in individuals with prehypertension or hypertension the DAYLIGHT trial
AU - Arora, Pankaj
AU - Song, Yanna
AU - Dusek, Jeffery
AU - Plotnikoff, Gregory
AU - Sabatine, Marc S.
AU - Cheng, Susan
AU - Valcour, Andre
AU - Swales, Heather
AU - Taylor, Beth
AU - Carney, Erin
AU - Guanaga, Derek
AU - Young, Joseph R.
AU - Karol, Courtney
AU - Torre, Michael
AU - Azzahir, Atum
AU - Strachan, Semerit M.
AU - O'Neill, Dillon C.
AU - Wolf, Myles
AU - Harrell, Frank
AU - Newton-Cheh, Christopher
AU - Wang, Thomas J.
N1 - Publisher Copyright:
© 2014 American Heart Association, Inc.
PY - 2015
Y1 - 2015
N2 - Background-A large body of epidemiological and experimental evidence suggests that vitamin D deficiency may promote hypertension. This raises the possibility that vitamin D supplementation could be a simple intervention to reduce blood pressure, but data from prospective, randomized trials are limited. Methods and Results-A double-blind, randomized, controlled trial was conducted at 4 sites in the United States. We enrolled 534 individuals 18 to 50 years of age with low vitamin D status (25-hydroxyvitamin D levels ≤25 ng/mL) and systolic blood pressure of 120 to 159 mm Hg. Participants were randomized to high-dose (4000 IU/d) versus low-dose (400 IU/d) oral vitamin D3 for 6 months. The primary end point was change in mean 24-hour systolic blood pressure. Secondary end points included change in ambulatory diastolic blood pressure and clinic systolic and diastolic blood pressures. The median age was 38 years, and 62% of participants were men. Forty-six percent of participants were white, and 48% were black. The median 25-hydroxyvitamin D level at baseline was 15.3 ng/mL. Four-hundred fiftyfive participants (85%) had at least 1 follow-up blood pressure measurement; 383 participants (72%) completed the full 6-month study. At the end of the study, there was no significant difference in the primary end point (change in mean 24-hour systolic blood pressure, -0.8 versus -1.6 mm Hg in the high-dose and low-dose arms; P=0.71) or in any of the secondary end points. Furthermore, there was no evidence of association between change in 25-hydroxyvitamin D and change in 24-hour systolic blood pressure at 6 months (Spearman correlation coefficient, -0.05, P=0.34). Results were consistent across prespecified subgroups. Conclusions-Vitamin D supplementation did not reduce blood pressure in individuals with prehypertension or stage I hypertension and vitamin D deficiency. Our findings suggest that the association between vitamin D status and elevated blood pressure noted in observational studies is not causal.
AB - Background-A large body of epidemiological and experimental evidence suggests that vitamin D deficiency may promote hypertension. This raises the possibility that vitamin D supplementation could be a simple intervention to reduce blood pressure, but data from prospective, randomized trials are limited. Methods and Results-A double-blind, randomized, controlled trial was conducted at 4 sites in the United States. We enrolled 534 individuals 18 to 50 years of age with low vitamin D status (25-hydroxyvitamin D levels ≤25 ng/mL) and systolic blood pressure of 120 to 159 mm Hg. Participants were randomized to high-dose (4000 IU/d) versus low-dose (400 IU/d) oral vitamin D3 for 6 months. The primary end point was change in mean 24-hour systolic blood pressure. Secondary end points included change in ambulatory diastolic blood pressure and clinic systolic and diastolic blood pressures. The median age was 38 years, and 62% of participants were men. Forty-six percent of participants were white, and 48% were black. The median 25-hydroxyvitamin D level at baseline was 15.3 ng/mL. Four-hundred fiftyfive participants (85%) had at least 1 follow-up blood pressure measurement; 383 participants (72%) completed the full 6-month study. At the end of the study, there was no significant difference in the primary end point (change in mean 24-hour systolic blood pressure, -0.8 versus -1.6 mm Hg in the high-dose and low-dose arms; P=0.71) or in any of the secondary end points. Furthermore, there was no evidence of association between change in 25-hydroxyvitamin D and change in 24-hour systolic blood pressure at 6 months (Spearman correlation coefficient, -0.05, P=0.34). Results were consistent across prespecified subgroups. Conclusions-Vitamin D supplementation did not reduce blood pressure in individuals with prehypertension or stage I hypertension and vitamin D deficiency. Our findings suggest that the association between vitamin D status and elevated blood pressure noted in observational studies is not causal.
KW - Blood pressure
KW - Dietary supplements
KW - Hypertension
KW - Vitamin D deficiency
UR - http://www.scopus.com/inward/record.url?scp=84925286472&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925286472&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.114.011732
DO - 10.1161/CIRCULATIONAHA.114.011732
M3 - Article
C2 - 25359163
AN - SCOPUS:84925286472
SN - 0009-7322
VL - 131
SP - 254
EP - 262
JO - Circulation
JF - Circulation
IS - 3
ER -